Abstract
A third of breast cancer diagnoses are made in women aged 70 years or over. Historically, older women have been regarded as presenting with tumors that are low grade and hormone sensitive and that are likely to have a good prognosis. However, in those older women whose tumors overexpress the HER2 oncogene, the prognosis is likely to be worse. Under these circumstances, due consideration should be given to adjuvant systemic therapy, including chemotherapy and targeted treatments, in order to minimize risks of disease recurrence. In this article we discuss the evidence base for the role of adjuvant systemic therapy in older women with HER2-positive early breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
